NASDAQ: CRSP · Life Sciences · 9 alerts · CIK 1674416
Share price
$40.37Close, Nov 16
Market cap
$3.92B
Shares outstanding
97MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Crispr Therapeutics AG filings on SEC EDGAR ↗
CRISPR Therapeutics reported Q3 2026 financial results, highlighted by $99 million in CASGEVY revenue, representing 30% quarter-over-quarter growth. The company also announced FDA RMAT designations for CTX310 and the appointments of a new Chief Technical Officer and Chief Financial Officer.
Term
Q3 2026
“The third quarter marked meaningful progress for CRISPR Therapeutics. CASGEVY is reaching more patients, including younger children following new approvals in the U.K. and the Middle East, and the FDA’s RMAT designations for CTX310 underscore its potential to address significant unmet needs in cardiovascular disease. With new clinical data from CTX310 and zugo-cel in the coming weeks and enrollment complete in our Phase 2 trial of CTX611, we are entering a pivotal period for our pipeline.”
Samarth Kulkarni, Ph.D., Chairman and Chief Executive Officer
Crispr Therapeutics CEO Samarth Kulkarni Sells $2.38M of Stock
Samarth Kulkarni, CEO, sold 47,837 shares of Crispr Therapeutics AG at $49.78 a share, worth $2.38M in total on Oct 19, 2026. Shares held after the trade: 311,899 (-13.3%).
CRISPR Therapeutics promoted Andrew J. Silver to Chief Financial Officer, effective October 19, 2026. Under his new employment agreement, Mr. Silver will receive an annual base salary of $515,000, a target bonus of 45%, and a one-time grant of 25,000 restricted stock units vesting over two years.
Crispr Therapeutics Director Simeon George Sells $720K of Stock
Simeon George, Director, sold 14,514 shares of Crispr Therapeutics AG at $49.63 a share, worth $720K in total on Oct 14, 2026. Shares held after the trade: 15,486 (-48.4%).
Crispr Therapeutics General Counsel and Secretary James R. Kasinger Sells $51.2K of Stock
James R. Kasinger, General Counsel and Secretary, sold 1,040 shares of Crispr Therapeutics AG at $49.26 a share, worth $51.2K in total on Oct 14, 2026. Shares held after the trade: 95,857 (-1.1%).
Crispr Therapeutics CEO Samarth Kulkarni Sells $202K of Stock
Samarth Kulkarni, CEO, sold 4,098 shares of Crispr Therapeutics AG at $49.26 a share, worth $202K in total on Oct 14, 2026. Shares held after the trade: 259,736 (-1.6%).
Crispr Therapeutics General Counsel and Secretary James R. Kasinger Sells $119K of Stock
James R. Kasinger, General Counsel and Secretary, sold 1,990 shares of Crispr Therapeutics AG at $60.04 a share, worth $119K in total on Oct 6, 2026. Shares held after the trade: 94,784 (-2.1%).
Crispr Therapeutics General Counsel and Secretary James R. Kasinger Sells $626K of Stock
James R. Kasinger, General Counsel and Secretary, sold 10,400 shares of Crispr Therapeutics AG at $60.24 a share, worth $626K in total on Sep 22, 2026. Shares held after the trade: 94,784 (-9.9%).
Crispr Therapeutics Director Ali Behbahani Sells $781K of Stock
Ali Behbahani, Director, sold 13,679 shares of Crispr Therapeutics AG at $57.09 a share, worth $781K in total on Sep 17, 2026. Shares held after the trade: 16,637 (-45.1%).